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Degradation of cellular regulatory proteins following their ubiq-
uitination plays a critical role in controlling multiple physiological
processes. Substrates of this pathway include tumor suppres-
sor proteins (p53), cell cycle proteins (p27Kip1), and transcription
factors (E2F-1, fos, jun, myc, NF-κB). More recently, receptor
tyrosine kinases (RTKs), including the colony-stimulating factor-
1 receptor (CSF-1R), the epidermal growth factor receptor
(EGFR), the hepatocyte growth factor receptor (HGFR/Met),
and the platelet-derived growth factor receptor (PDGFR), have
been identified as substrates for ubiquitination.
RTKs are single pass transmembrane proteins that control
a wide variety of cellular events in pluricellular organisms
including cell proliferation, cell differentiation, cell migration, and
cell survival. In normal cells, RTK activation is tightly regulated.
Their inappropriate activation is associated with the develop-
ment and progression of many human malignancies. Of the 58
genes known to encode RTKs, the deregulation of 30 has been
associated with human tumors (Blume-Jensen and Hunter,
2001). In the past two decades, several mechanisms that dereg-
ulate RTKs, such as receptor amplification, chromosomal
translocation, and point mutations, have been identified. These
changes result in ligand-independent activation or enhanced
catalytic activity of RTKs (Blume-Jensen and Hunter, 2001;
Lamorte and Park, 2001). However, in addition to these positive
mechanisms, there is growing evidence that escape from
negative regulatory mechanisms is an important event in RTK
deregulation. In this review, we will examine how different RTK-
derived oncoproteins escape downregulation.
In the absence of ligand, most RTKs are catalytically
inactive. Binding of the ligand promotes receptor
dimerization/oligomerization and induces a conformational
change that triggers receptor kinase activity. Tyrosine residues
on the receptor then become phosphorylated, forming binding
sites for proteins that relay the biological signals. RTK activation
promotes their internalization via clathrin-coated pits. The
downregulation of tyrosine kinase activity and hence signaling
can be modulated reversibly through the action of tyrosine
phosphatases as well as irreversibly through their lysosomal
degradation. Recent publications have established that ubiquiti-
nation plays a major role in RTK downregulation by targeting
receptors to the lysosome (Shtiegman and Yarden, 2003).
Protein ubiquitination is mediated by an enzymatic cascade
composed of a ubiquitin-activating enzyme (E1), a ubiquitin-
conjugating enzyme (E2), and a ubiquitin-protein ligase (E3). A
single 76 amino acid ubiquitin moiety is covalently conjugated
to a lysine residue within the substrate protein. Additional ubiq-
uitin residues can be added to lysine residues within the linked
ubiquitin to generate polyubiquitin chains. The presence of a
polyubiquitin chain on many cytosolic and nuclear proteins tar-
gets them for degradation by the 26S proteasome. In contrast,
ubiquitination of many cell surface receptors correlates with
their internalization and lysosomal degradation.Monoubiquitination
of EGFR is sufficient for its internalization, and some evidence
supports that EGFR and PDGFR are multimonoubiquitinated
rather then being polyubiquitinated (Haglund et al., 2003;
Mosesson et al., 2003).
Monoubiquitin moieties can constitute binding sites for pro-
teins that contain ubiquitin binding domains such as ubiquitin
interaction motif (UIM), ubiquitin-associated (UBA), and ubiqui-
tin-conjugating-like (UBC-like) domains. The UIM-containing
proteins, HRS and STAM, are thought to recruit ubiquitinated
RTKs to ESCRT complexes that retain receptors in specialized
microdomains of sorting endosomes characterized by a bilay-
ered clathrin coat, from which receptors internalize into the
endosomal lumen (Figure 1) (Clague, 2002). Sorting endo-
somes mature into multivesicular bodies (MVBs) where recep-
tors remained trapped within internal vesicles. Fusion of MVBs
with lysosomes leads to the degradation of internal vesicles and
their content. RTKs that are not ubiquitinated are not sorted in
the bilayered clathrin coat, can recycle back to the cell surface,
and escape lysosomal degradation (Figure 1) (Katzmann et al.,
2002).
The Cbl family of ubiquitin-protein ligases (c-Cbl, Cbl-b, and
Cbl-3) plays a major role in the ligand-dependent ubiquitination
of many RTKs (Thien and Langdon, 2001). Several receptors
including EGFR, PDGFR, CSF-1R, and Met (HGFR) are ubiqui-
tinated following recruitment of c-Cbl. Cbl ubiquitin-protein ligas-
es are modular proteins that contain a conserved N-terminal
tyrosine kinase binding (TKB) domain and a RING finger
domain in addition to other protein interaction motifs (Thien
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and Langdon, 2001). Where tested, the TKB domain inter-
acts with specific phosphotyrosine residues on RTKs.The RING
finger domain recruits the E2 ubiquitin-conjugating enzyme,
UbcH7. Both domains are required for the transfer of ubiquitin
residues to RTKs. Moreover, the stability of c-Cbl is itself regu-
lated by ubiquitination. Tyrosine phosphorylation of c-Cbl by the
c-Src protein tyrosine kinase promotes auto-ubiquitination of c-
Cbl and its degradation in a proteasome-dependent manner
(Yokouchi et al., 2001). The observation that Cbl proteins can
also interact with ubiquitin-protein ligases containing HECT
(homologous to E6-AP C terminus) domains suggests a poten-
tial additional layer of regulation (Courbard et al., 2002).
In addition to the targeting of RTKs for lysosomal degrada-
tion following ubiquitination, several lines of evidence support a
role for c-Cbl in the internalization of RTKs. The overexpression
of c-Cbl enhances the rate of internalization of EGFR
(Levkowitz et al., 1999; Soubeyran et al., 2002), whereas in c-
Cbl null macrophages, CSF-1R has a slower rate of internaliza-
tion (Lee et al., 1999). It has been proposed that c-Cbl promotes
the internalization of EGFR and the Met receptor through its
ability to recruit CIN85 and endophilins (Petrelli et al., 2002;
Soubeyran et al., 2002). During RTK internalization, endophilins
are thought to induce negative membrane curvature required
for the invagination of the plasma membrane into pits.
Consistent with its role in the downmodulation of RTKs,
mutant c-Cbl proteins that lack ubiquitin ligase activity have
been identified in mouse tumors and as retrovirally transduced
transforming proteins (Thien and Langdon, 2001). These pro-
teins retain the ability to bind to phosphotyrosine residues on
RTKs, yet fail to ubiquitinate the receptor. Hence, they are
thought to compete with the binding of wt Cbl proteins to RTKs
and to transform cells through their ability to potentiate RTK
signals.
Recently, it has become evident that several oncogenic
RTKs have lost the ability to recruit Cbl in a TKB-mediated man-
ner (Met/HGFR, CSF-1R, c-Kit/SCFR, EGFR). These receptors
normally recruit Cbl following ligand stimulation, and for several
of them, Cbl has been shown to promote receptor ubiquitination
and enhanced degradation.
Hepatocyte growth factor receptor
The c-Cbl TKB domain binds to a juxtamembrane tyrosine
(1003) residue on the Met receptor, and this interaction is
essential for ubiquitination and degradation of the Met receptor
(Peschard et al., 2001). An oncogenic form of the Met receptor,
Tpr-Met, was generated following a carcinogen-induced chro-
mosomal rearrangement that fused a protein dimerization
domain (Tpr) to the kinase domain of the Met receptor. This
results in the deletion of the juxtamembrane tyrosine binding
site for c-Cbl (Y1003).The Tpr-Met RTK oncoprotein is constitu-
tively activated, but fails to bind c-Cbl and is not ubiquitinated
(Figure 2) (Peschard et al., 2001). This suggested that loss of
Cbl recruitment and ubiquitination contribute to the oncogenic
deregulation of Tpr-Met. Notably, a Met receptor mutant that
lacks only the c-Cbl TKB domain binding site (Y1003F) has a
prolonged half-life and is oncogenic in cell culture and tumorige-
nesis assays, identifying c-Cbl and ubiquitination as important
negative regulators for this receptor (Peschard et al., 2001).
Another member of the Met family of RTKs, c-Sea, was original-
ly isolated as the cellular homolog of the avian erythroblastosis
retroviral oncoprotein v-Sea. Like Tpr-Met, the c-Cbl TKB bind-
ing site located in the juxtamembrane domain of c-Sea is delet-
ed in the v-Sea oncogenic receptor (Figure 2).
Colony-stimulating factor-1 receptor
In a similar manner, the CSF-1R was first identified as a viral
oncogene, v-Fms, the product of the McDonough strain of feline
sarcoma virus. One of the several structural differences
between c-Fms/CSF-1R and v-Fms is the replacement of the
CSF-1R carboxy-terminal 50 amino acids that contain the direct
binding site for the c-Cbl TKB domain (tyrosine 969) by 14 unre-
lated amino acids in v-Fms (Figure 2) (Mancini et al., 2002;
Wilhelmsen et al., 2002).The deletion of the c-Cbl direct binding
site in v-Fms renders v-Fms refractory to c-Cbl-dependent ubiq-
uitination, and the addition of the c-Cbl TKB domain binding site
to v-Fms decreases its transforming activity (Mancini et al.,
2002). Consistent with these observations, mutation of the C-
terminal tyrosine 969, the direct binding site for c-Cbl, enhanced
the transforming ability of CSF-1R in fibroblasts (Roussel et al.,
1988). Mutations of the Cbl binding site are frequently observed
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Figure 1. RTK ubiquitination and downregulation
Subsequent to the activation of several RTKs, c-
Cbl is recruited to the receptor and induces
receptor ubiquitination. Following internaliza-
tion, ubiquitinated RTKs (green) are enriched in
an endosomal microdomain characterized by
a bilayered clathrin coat. Receptors are subse-
quently internalized in inner vesicles. The
process of receptor enrichment and subse-
quent internalization involves multiple proteins
that contain ubiquitin-interacting motifs (Hrs,
Stam, and proteins of the ESCRT complexes) as
well as deubiquitinating enzymes (DUBs) that
remove ubiquitin moieties from the receptors.
Fusion of multivesicular bodies with lysosomes
leads to the degradation of inner vesicles and
their content by lysosomal proteases. RTKs that
are not ubiquitinated (red) are not sequestered
in the bilayered clathrin coat of the sorting
endosomes and can be recycled to the cell
surface where they can be reactivated. Such
receptors may be inactivated through dephos-
phorylation.
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in CSF-1R in human myelodysplasia (8 out of 67 cases) and
acute myeloblastic leukemia (8 out of 48 cases), further impli-
cating loss of c-Cbl binding in oncogenic deregulation of CSF-
1R in human cancer (Ridge et al., 1990).
Stem cell factor receptor, c-Kit
The recruitment of c-Cbl to the stem cell factor (SCF) recep-
tor/c-Kit and to PDGFRβ occurs indirectly via the APS (adaptor
containing PH and SH2 domains) protein. This association
leads to PDGFR downregulation (Yokouchi et al., 1999).
Notably, the two APS binding sites in c-Kit, tyrosine 568 located
in the juxtamembrane domain and tyrosine 936 located in the
carboxy-terminal region of the receptor (Wollberg et al., 2003),
are absent in v-Kit, the transforming protein of the Hardy-
Zuckerman-4 strain of feline sarcoma virus (Figure 2).
Moreover, the deletion of APS binding sites in c-Kit greatly
enhanced its transforming ability (Herbst et al., 1995), although
some of this may be attributed to the loss of negative regulation
through juxtamembrane tyrosine 568 and enhanced catalytic
activity of the receptor (Chan et al., 2003).
Epidermal growth factor receptor
Upon activation of EGFR (ErbB1), c-Cbl proteins are rapidly
recruited and remain associated with the receptor as it pro-
gresses through the endocytic pathway (de Melker et al., 2001).
Tyrosine 1045 constitutes the direct binding site for the c-Cbl
TKB domain and is required for c-Cbl-mediated ubiquitination
and degradation of EGFR (Levkowitz et al., 1999). Interestingly,
the v-erbB protein encoded by the avian erythroblastosis virus
AEV-C has, among other alterations, an internal deletion of 21
amino acids that comprises the c-Cbl TKB domain binding site
(Figure 2) (Choi et al., 1986). Moreover, in a similar manner to
both HGF and CSF-1 receptors, an EGFR
mutant lacking only the direct Cbl binding
site elicits stronger mitogenic signals than
the wt receptor (Waterman et al., 2002).
Up to 40% of glioblastomas express
oncogenic mutants of EGFR. The most
common genetic alteration consists of a
deletion of exons 2–7 located in the extra-
cellular domain of EGFR (67% of all
EGFR genetic alterations) (Frederick et
al., 2000). The resulting protein
(EGFRvIII) is constitutively activated, but
has low levels of tyrosine phosphoryla-
tion. EGFRvIII receptors have a reduced
ability to recruit Cbl proteins and CIN85,
and are neither ubiquitinated nor internal-
ized (Schmidt et al., 2003), suggesting
that basal receptor activation is sufficient
to confer tumorigenicity, but not sufficient
to trigger Cbl-mediated downregulation.
Another genetic alteration of EGFR identi-
fied in human glioblastoma generates a
truncated receptor (EGFRvV) that has an
intact kinase domain, but that is missing the c-Cbl TKB direct
binding site (Y1045) and the internalization signals (Figure 2)
(Frederick et al., 2000).
Another member of the EGF receptor family, HER2/ErbB2,
is overexpressed in many human tumors such as breast, ovary,
prostate, and brain tumors. Overexpression of HER2 shifts the
formation of EGFR homodimers toward the formation of
EGFR/HER2 heterodimers. While ligand-stimulated EGFR
homodimers undergo rapid ubiquitination, internalization, and
degradation, EGFR/HER2 heterodimers recruit c-Cbl to a
reduced extent, are slowly internalized, and recycle rapidly to
the cell surface (Lenferink et al., 1998; Muthuswamy et al.,
1999). The delay in EGFR/HER2 heterodimer degradation
potentiates EGFR-dependent cell proliferation, cell migration,
and antiapoptotic signals. Hence, the overexpression of HER2
constitutes a mechanism through which EGFR escapes Cbl-
mediated downregulation. Indeed, overexpression or amplifica-
tion of Cbl binding RTKs, as frequently observed in human
cancers, could act as a mechanism to sequester Cbl proteins,
enhancing the stability of other RTKs that are Cbl substrates. In
addition, the deregulation of Src, which occurs in human colon,
breast, lung, and brain cancers, leads to the stabilization of the
EGFR by promoting c-Cbl ubiquitination and degradation (Bao
et al., 2003).
Besides point mutations and overexpression, RTKs are fre-
quently activated in human tumors following chromosomal
translocation. In general, this fuses a protein dimerization
domain with the cytosolic kinase domain of the receptor, result-
ing in constitutive receptor dimerization and activation (Lamorte
and Park, 2001). Over 25 RTK-derived fusion proteins have
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Figure 2. Loss of TKB-mediated Cbl binding in sev-
eral RTK-derived oncoproteins
The binding of the c-Cbl TKB domain to the EGF,
CSF-1, and Met receptors is required for receptor
ubiquitination and degradation. Loss of TKB-medi-
ated Cbl binding to RTKs correlates with a gain of
transforming ability, suggesting that it constitutes
an important event in RTK oncogenic deregulation.
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been identified in human tumors. In each case, the N-terminal
signal peptide, necessary for protein targeting to the mem-
brane, is deleted in the rearranged kinase and, with the excep-
tion of FIG-ROS that is targeted to the golgi (Charest et al.,
2003), where studied, these proteins are cytosolic (Lamorte
and Park, 2001). Localization to the cytosol would preclude their
entry in the endocytic pathway and hence, their lysosomal tar-
geting and degradation. However, it remains to be determined
whether these oncoproteins are ubiquitinated and targeted for
degradation by the proteasomal pathway.
Conclusion
In the past few years, the discovery that Cbl proteins are ubiqui-
tin-protein ligases and that ubiquitination regulates receptor
sorting to lysosomes has greatly improved our understanding of
the molecular mechanisms that downregulate RTKs. We bring
to light evidence that many RTK-derived oncoproteins avoid
downregulation by loss of Cbl binding sites, inefficient Cbl
recruitment, Cbl degradation, or through the formation of fusion
proteins that escape lysosomal degradation. These constitute
some mechanisms among several that promote the stabilization
of RTKs. Overall, an understanding of the mechanisms through
which RTKs are downmodulated will allow new therapeutic
approaches to target these RTKs for degradation in cancer. In
this respect, Trastuzumab, a drug used in combination with
chemotherapy for the treatment of metastatic breast cancer, is a
weak agonist of HER2.Trastuzumab is thought to force receptor
dimerization and potentiate recruitment of Cbl and receptor
downregulation (Klapper et al., 2000). Similar drugs designed to
force other RTKs toward a degradation pathway would likely be
beneficial in the design of therapeutic strategies for cancer.
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